Lilly’s EBGLYSS Wins FDA Approval for Reduced Injection Schedule
INDIANAPOLIS, United States, June 9, 2026 Eli Lilly and Company has secured U.S. Food and Drug Administration (FDA) approval...
eczema treatment
Advertisement
Apogee Therapeutics Lands $1.3B Blackstone Deal
SAN FRANCISCO and BOSTON, May 27, 2026 Apogee Therapeutics announced a landmark $1.3 billion strategic financing collaboration with Blackstone...
Apogee to Reveal Phase 2 Zumilokibart AD Data
SAN FRANCISCO and BOSTON, May 26, 2026 Apogee Therapeutics announced it will report Part B 16-week clinical data from...
Incyte Opzelura Shows Durable Atopic Dermatitis Benefit
WILMINGTON, Del., May 7, 2026 Incyte announced positive 24-week long-term results from the Phase 3 TRuE-AD4 clinical trial evaluating...
Advertisement
